Yang Guang Hua, Ma Xu Dong, Wei Xi Feng, Liu Ran Lu, Wang Chao
Department of Urology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Comb Chem High Throughput Screen. 2025;28(4):691-710. doi: 10.2174/0113862073296897240212114403.
The efficacy of chemotherapy in treating Kidney Renal Clear Cell Carcinoma (KIRC) is limited, whereas immunotherapy has shown some promising clinical outcomes. In this context, KIF4A is considered a potential therapeutic target for various cancers. Therefore, identifying the mechanism of KIF4A that can predict the prognosis and immunotherapy response of KIRC would be of significant importance.
Based on the TCGA Pan-Cancer dataset, the prognostic significance of the KIF4A expression across 33 cancer types was analyzed by univariate Cox algorithm. Furthermore, overlapping differentially expressed genes (DEGs1) between the KIF4A high- and lowexpression groups and DEGs2 between the KIRC and normal groups were also analyzed. Machine learning and Cox regression algorithms were performed to obtain biomarkers and construct a prognostic model. Finally, the role of KIF4A in KIRC was analyzed using quantitative real-time PCR, transwell assay, and EdU experiment.
Our analysis revealed that KIF4A was significant for the prognosis of 13 cancer types. The highest correlation with KIF4A was found for KICH among the tumour mutation burden (TMB) indicators. Subsequently, a prognostic model developed with UBE2C, OTX1, PPP2R2C, and RFLNA was obtained and verified with the Renal Cell Cancer-EU/FR dataset. There was a positive correlation between risk score and immunotherapy. Furthermore, the experiment results indicated that KIF4A expression was considerably increased in the KIRC group. Besides, the proliferation, migration, and invasion abilities of KIRC tumor cells were significantly weakened after KIF4A was knocked out.
We identified four KIF4A-related biomarkers that hold potential for prognostic assessment in KIRC. Specifically, early implementation of immunotherapy targeting these biomarkers may yield improved outcomes for patients with KIRC.
化疗在治疗肾透明细胞癌(KIRC)方面的疗效有限,而免疫疗法已显示出一些有前景的临床结果。在此背景下,KIF4A被认为是多种癌症的潜在治疗靶点。因此,确定KIF4A能够预测KIRC预后和免疫治疗反应的机制具有重要意义。
基于TCGA泛癌数据集,采用单因素Cox算法分析KIF4A在33种癌症类型中的表达的预后意义。此外,还分析了KIF4A高表达组和低表达组之间的重叠差异表达基因(DEGs1)以及KIRC组和正常组之间的DEGs2。进行机器学习和Cox回归算法以获得生物标志物并构建预后模型。最后,使用定量实时PCR、Transwell实验和EdU实验分析KIF4A在KIRC中的作用。
我们的分析表明,KIF4A对13种癌症类型的预后具有重要意义。在肿瘤突变负担(TMB)指标中,KICH与KIF4A的相关性最高。随后,获得了一个由UBE2C、OTX1、PPP2R2C和RFLNA构建的预后模型,并使用肾细胞癌 - 欧盟/法国数据集进行了验证。风险评分与免疫治疗之间存在正相关。此外,实验结果表明KIRC组中KIF4A表达显著增加。此外,敲除KIF4A后,KIRC肿瘤细胞的增殖、迁移和侵袭能力明显减弱。
我们确定了四种与KIF4A相关的生物标志物,它们在KIRC的预后评估中具有潜力。具体而言,针对这些生物标志物尽早实施免疫治疗可能会改善KIRC患者的预后。